Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

NCT03309878 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

8

Enrollment

NIH

Sponsor class

Conditions

Recurrent Diffuse Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Transformed B-Cell Non-Hodgkin Lymphoma

Interventions

BIOLOGICAL: Mogamulizumab
BIOLOGICAL: Pembrolizumab

Sponsor

National Cancer Institute (NCI)